Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids found in such plants as gender Berberis. Berberine is recognised to improve glucose and lipid metabolism disorders and preliminary clinical evidences suggest the ability of berberine to reduce endothelial inflammation improving vascular health, even in patients already affected by cardiovascular diseases, suggesting a possible interesting role of berberine and its metabolites in clinical practice. However, its physicochemical properties, pharmacokinetic, and metabolism are not fully elucidated and contradictory data have been reported. This review provides a summary regarding the pharmacological and biological features of berberine, with a focus on berberine as well as their pharmacologically active metabolites and the different mechanisms underlying their activities in order to clarify the correct use of berberine supplementation, alone or in association with other nutraceuticals, for the management of metabolic disorders associated to increased cardiovascular disease risk. A particular attention has also been given to the available clinical trials assessing its short- and middle- term use tolerability, safety and efficacy in various conditions, such as dyslipidaemia, impaired fasting glucose, metabolic syndrome and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549 · cited 1×
“These suggestions have also been supported by the recent new European guidelines of the management of dyslipidemias [7] that also added some nutraceuticals as potentially useful lipid-lowering substances.”
ResultKong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 1×
“Zhang (2008) [121] Type 2 diabetes 116 1000 mg/day 12 weeks Reduction of BMI by 0.”
BackgroundKukidome, D., Nishikawa, T., Sonoda, K., Imoto, K., Fujisawa, K., Yano, M., Motoshima, H., Taguchi, T., Matsumura, T., & Araki, E. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0943 · Cited by 504 · cited 4×
“(SOD) [67, 68], which promotes the dismutation of anion superoxide in hydrogen peroxide.”
BackgroundInfluentialLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458
Banegas, J. R., Lopez-Garcia, E., Dallongeville, J., Guallar, E., Halcox, J. P., Borghi, C., Masso-Gonzalez, E. L., Jimenez, F. J., Perk, J., Steg, P. G., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr080 · Cited by 354 · cited 1×
“Despite the efforts towards primary prevention, cardiovascular diseases are yet the most common causes of death and one of the first causes of disability in industrialized countries [1].”
BackgroundTransforming berberine into its intestine-absorbable form by the gut microbiota
Feng, R., Shou, J.-W., Zhao, Z.-X., He, C.-Y., Ma, C., Huang, M., Fu, J., Tan, X.-S., Li, X.-Y., Wen, B.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep12155 · Cited by 307 · cited 1×
“Intestinal bacterial microflora plays a pivotal role in enterohepatic circulation of BBR and its conjugated metabolites: recent reports demonstrated that an intestinal microbiota of healthy subjects is essential to convert BBR in its absorbable forms [24].”
BackgroundWang, S., Zhang, M., Liang, B., Xu, J., Xie, Z., Liu, C., Viollet, B., Yan, D., & Zou, M.-H. (2010) · Circulation Research · doi:10.1161/circresaha.109.212530 · Cited by 296 · cited 1×
“NOX could be negatively regulated by AMPK activation [59, 60]; in fact, AMPK activators, such as metformin, may exert their cardiovascular protective function through NOX inhibition [61].”
BackgroundTissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats
Tan, X.-S., Ma, J.-Y., Feng, R., Ma, C., Chen, W.-J., Sun, Y.-P., Fu, J., Huang, M., He, C.-Y., Shou, J.-W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077969 · Cited by 266 · cited 1×
“Moreover, as it is reported by Tan and colleagues, after oral intake BBR is rapidly distributed in the body with maximum concentration in liver, followed by kidneys, muscle, lungs, brain, heart, pancreas and fat [32].”
BackgroundDerosa, G., Maffioli, P., & Cicero, A. F. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.704014 · Cited by 171 · cited 1×
“Recent reports demonstrated the effectiveness of BBR supplementation in lipid disorders and hyperglycemia [13], even if the physico-chemical properties as well as the bioavailability of BBR and its metabolites, are not yet fully elucidated.”
BackgroundSelf-citation
Cited by
The metabolism of berberine and its contribution to the pharmacological effects
Wang, K., Feng, X., Chai, L., Cao, S., & Qiu, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1306544 · Cited by 502
Biological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
Poli, A., Barbagallo, C. M., Cicero, A. F. G., Corsini, A., Manzato, E., Trimarco, B., Bernini, F., Visioli, F., Bianchi, A., Canzone, G., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.05.015 · Cited by 134
Self-citationSut, S., Faggian, M., Baldan, V., Poloniato, G., Castagliuolo, I., Grabnar, I., Perissutti, B., Brun, P., Maggi, F., Voinovich, D., et al. (2017) · Molecules · doi:10.3390/molecules22111921 · Cited by 120
“Furthermore berberine is also considered potentially useful for its anti-inflammatory activity and ability to decrease free radical levels, helping the protection of the endothelial function [3,5,7].”
The mechanism of berberine alleviating metabolic disorder based on gut microbiome
Wang, H., Zhang, H., Gao, Z., Zhang, Q., & Gu, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.854885 · Cited by 69
“Its mechanism of utility has also been extensively and intensively studied (Caliceti et al., 2016), a large number of experimental studies have shown that berberine alleviates body metabolism and insulin resistance through a variety of mechanisms, such as amelioration of oxidative stress, inhibition of macrophage infl…”
Background
Metadata
- Authors
- Caliceti, C., Franco, P., Spinozzi, S., Roda, A., & F.G. Cicero, A.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-05-13
- Volume
- 23
- Issue
- 14
- Pages
- 1460-1476
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2340190976
- Cited by
- 91
- References
- 21
- FWCI
- 9.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. https://app.cochat.ai/papers/10.2174/0929867323666160411143314
- The paper
- Caliceti, C., Franco, P., Spinozzi, S., Roda, A., & F.G. Cicero, A. (2016). Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders. Current Medicinal Chemistry. https://doi.org/10.2174/0929867323666160411143314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.